The potential use of denosumab in patients with arthroplasty

Despite the excellent clinical results achieved by total hip arthroplasty, particles generated through wear and the subsequent biologic response of periprosthetic osteolysis still continue to be a concern.

Serious adverse consequences frequently become evident 10–20 years after arthroplasty surgery when the patient might be less physically fit than at the time of the initial surgery, and therefore less equipped for the major challenges of difficult revision surgery. In this context, the concept of non-surgical pharmacological treatment of periprosthetic osteolysis, reported in The Lancet Rheumatology by Mohit M Mahatma and colleagues,

brings a new hope for the ever-increasing population of patients with total hip arthroplasty to avoid revision surgery.